Actively Recruiting
A Phase 1 Study Comparing the Safety and Drug Levels of AD-228B and AD-2284 in Healthy Adults Using a Single Dose Crossover Design
Led by Addpharma Inc. · Updated on 2025-03-20
60
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the pharmacokinetic characteristics of two oral drugs, AD-228B and AD-2284, in healthy adult volunteers. This Phase 1, open-label, randomized crossover study aims to compare how these drugs behave in the body, focusing on their concentration in the blood over time to assess bioequivalence. The study is sponsored by Addpharma Inc. and targets adults with primary hypercholesterolaemia as healthy volunteers. The study includes two treatment periods where participants receive a single oral dose of either AD-228B or AD-2284 in a randomized sequence. Period 1 participants receive one drug, and Period 2 participants receive the other, allowing direct comparison within the same individuals. No placebo or blinding is used, and the study uses a fasting condition to standardize drug absorption. Participants will be monitored for drug concentrations in their plasma from before dosing up to 72 hours after each dose. Researchers will measure maximum drug concentration and the area under the concentration-time curve to evaluate how the drugs are processed. The total participation timeline includes both treatment periods and follow-up assessments up to three days post-dose to gather necessary pharmacokinetic data.
CONDITIONS
Brief Title
A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284
Research Team
J
JeongEun Park
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here